Flagship Pioneering has announced the formation of Etcelera, a company created by the merger of the platforms of Cellarity, Etiome and Empress Therapeutics. The new company aims to pioneer causal intelligence in human biology: the ability to determine what truly drives disease and predict how a medicine… Read More
Biotechnology company Flagship Pioneering has unveiled its generative AI platform Expedition Medicines, backed by $50 million in funding. Flagship believes Expedition Medicines will push the boundaries in medicine to enable the creation of first-in-class therapies across oncology, immunology and other diseases. The platform can learn the rules… Read More
Data demonstrate that engineered tRNA from Alltrna’s first development candidate restores protein production to clinically meaningful levels in two disease models driven by the same premature termination codon. AP003 is a chemically modified, engineered tRNA oligonucleotide in a clinically validated, liver-directed lipid nanoparticle (LNP) that can readthrough… Read More
Pfizer has expanded its strategic partnership with Flagship Pioneering, adding two new research programmes with Flagship-founded Quotient Therapeutics. Under the collaboration, the companies will analyse somatic mutations that occur in diseased patient tissue to inform the discovery and development of therapies for cardiovascular and renal diseases. Read More
Flagship Pioneering and ProFound Therapeutics have announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity. The collaboration is the first initiated under Flagship’s Pioneering Medicines strategic partnership with Pfizer announced in July 2023. Pioneering Medicines,… Read More
